作者
Elena Martínez-Terroba, Carmen Behrens, Jackeline Agorreta, Eduard Monsó, Laura Millares, Enriqueta Felip, Rafael Rosell, José Luis Ramirez, Ana Remirez, Wenceslao Torre, Ignacio Gil-Bazo, Miguel A Idoate, Juan P De-Torres, Ruben Pio, Ignacio I Wistuba, María J Pajares, Luis M Montuenga
发表日期
2019/4/1
期刊
Thorax
卷号
74
期号
4
页码范围
371-379
出版商
BMJ Publishing Group Ltd
简介
Introduction
Prognostic biomarkers have been very elusive in the lung squamous cell carcinoma (SCC) and none is currently being used in the clinical setting. We aimed to identify and validate the clinical utility of a protein-based prognostic signature to stratify patients with early lung SCC according to their risk of recurrence or death.
Methods
Patients were staged following the new International Association for the Study of Lung Cancer (IASLC) staging criteria (eighth edition, 2018). Three independent retrospective cohorts of 117, 96 and 105 patients with lung SCC were analysed to develop and validate a prognostic signature based on immunohistochemistry for five proteins.
Results
We identified a five protein-based signature whose prognostic index (PI) was an independent and significant predictor of disease-free survival (DFS) (p<0.001; HR=4.06, 95% CI 2.18 to 7.56) and overall survival (OS) (p=0.004; HR=2.38 …
学术搜索中的文章
E Martínez-Terroba, C Behrens, J Agorreta, E Monsó… - Thorax, 2019